Analyst Price Targets — PHVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 8:39 pm | — | Wolfe Research | $42.00 | $27.56 | TheFly | Pharvaris initiated with an Outperform at Wolfe Research |
| March 9, 2026 9:20 am | — | RBC Capital | $52.00 | $26.51 | TheFly | Pharvaris initiated with an Outperform at RBC Capital |
| December 4, 2025 12:35 pm | — | Oppenheimer | $50.00 | $29.37 | TheFly | Pharvaris price target raised to $50 from $44 at Oppenheimer |
| December 4, 2025 12:23 pm | Debjit Chattopadhyay | Guggenheim | $39.00 | $29.37 | TheFly | Pharvaris price target raised to $39 from $32 at Guggenheim |
| December 4, 2025 12:12 am | Maxwell Skor | Morgan Stanley | $41.00 | $29.37 | TheFly | Pharvaris price target raised to $41 from $37 at Morgan Stanley |
| December 3, 2025 7:56 pm | — | Leerink Partners | $38.00 | $29.37 | TheFly | Pharvaris price target raised to $38 from $28 at Leerink |
| October 15, 2025 10:09 am | — | H.C. Wainwright | $60.00 | $20.96 | TheFly | Pharvaris initiated with a Buy at H.C. Wainwright |
| October 14, 2024 6:08 am | Justin Kim | Oppenheimer | $42.00 | $19.73 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Pharvaris B.V. (PHVS) |
| April 11, 2024 6:12 am | Jonathan Wolleben | JMP Securities | $50.00 | $22.27 | TheFly | Pharvaris price target raised to $50 from $49 at JMP Securities |
| September 25, 2023 3:47 pm | Laura Chico | Wedbush | $27.00 | $20.67 | Benzinga | Pharvaris' Promising Oral Treatment Solutions For Treating Swollen Blood Vessels - Analyst Sees 35% Upside |
Latest News for PHVS
This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a year of sharp share price gains.
Tudor Investment Corp ET AL purchased a new stake in Pharvaris N.V. (NASDAQ: PHVS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 77,891 shares of the company's stock, valued at approximately $1,943,000. Tudor Investment Corp ET AL
ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the fourth quarter and…
The mean of analysts' price targets for Pharvaris (PHVS) points to a 59.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that two articles have been published…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PHVS.
U.S. House Trading
No House trades found for PHVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.